[go: up one dir, main page]

HK1243368A1 - 丁丙諾啡給藥方案 - Google Patents

丁丙諾啡給藥方案

Info

Publication number
HK1243368A1
HK1243368A1 HK18102786.4A HK18102786A HK1243368A1 HK 1243368 A1 HK1243368 A1 HK 1243368A1 HK 18102786 A HK18102786 A HK 18102786A HK 1243368 A1 HK1243368 A1 HK 1243368A1
Authority
HK
Hong Kong
Prior art keywords
dosing regimens
buprenorphine dosing
buprenorphine
regimens
dosing
Prior art date
Application number
HK18102786.4A
Other languages
English (en)
Inventor
Azmi Nasser
Original Assignee
Indivior Uk Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=55221448&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HK1243368(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Indivior Uk Ltd filed Critical Indivior Uk Ltd
Publication of HK1243368A1 publication Critical patent/HK1243368A1/zh

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/485—Morphinan derivatives, e.g. morphine, codeine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Emergency Medicine (AREA)
  • Neurosurgery (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Addiction (AREA)
  • Dermatology (AREA)
  • Inorganic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
HK18102786.4A 2014-11-07 2018-02-27 丁丙諾啡給藥方案 HK1243368A1 (zh)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201462076854P 2014-11-07 2014-11-07
US201562100391P 2015-01-06 2015-01-06
US201562112546P 2015-02-05 2015-02-05
US201562199778P 2015-07-31 2015-07-31
PCT/IB2015/002269 WO2016071767A1 (en) 2014-11-07 2015-11-06 Buprenorphine dosing regimens

Publications (1)

Publication Number Publication Date
HK1243368A1 true HK1243368A1 (zh) 2018-07-13

Family

ID=55221448

Family Applications (1)

Application Number Title Priority Date Filing Date
HK18102786.4A HK1243368A1 (zh) 2014-11-07 2018-02-27 丁丙諾啡給藥方案

Country Status (11)

Country Link
US (5) US20160128997A1 (zh)
EP (1) EP3215223B1 (zh)
AU (1) AU2015341490C1 (zh)
CA (2) CA3015557C (zh)
DK (1) DK3215223T3 (zh)
ES (1) ES2808150T3 (zh)
HK (1) HK1243368A1 (zh)
IL (1) IL251870A0 (zh)
NZ (1) NZ731309A (zh)
SG (1) SG11201703632WA (zh)
WO (1) WO2016071767A1 (zh)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3215223B1 (en) 2014-11-07 2020-07-01 Indivior UK Limited Buprenorphine dosing regimens
US10646484B2 (en) * 2017-06-16 2020-05-12 Indivior Uk Limited Methods to treat opioid use disorder
AU2018283724B2 (en) * 2017-06-16 2021-08-19 Indivior Uk Limited Methods to treat opioid use disorder
ES2965836T3 (es) 2018-01-22 2024-04-17 Foresee Pharmaceuticals Co Ltd Composición farmacéutica para administración de liberación mantenida de buprenorfina
WO2020077235A1 (en) * 2018-10-11 2020-04-16 Indivior Uk Limited Buprenorphine to treat respiratory depression
KR20210114940A (ko) * 2018-12-14 2021-09-24 페어 테라퓨틱스, 인코포레이티드 부프레노르핀-함유 제품들의 유도를 최적화하기 위한 디지털 치료 컴포넌트
US20220138539A1 (en) * 2020-10-30 2022-05-05 Element Ai Inc. Covariate processing with neural network execution blocks

Family Cites Families (73)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB784659A (en) 1954-11-26 1957-10-16 Upjohn Co Therapeutic compositions and aqueous suspensions thereof
US4599354A (en) 1985-03-11 1986-07-08 Morton Shulman Composition and method for producing prolonged pain relief
US4804663A (en) 1985-03-27 1989-02-14 Janssen Pharmaceutica N.V. 3-piperidinyl-substituted 1,2-benzisoxazoles and 1,2-benzisothiazoles
US5702716A (en) 1988-10-03 1997-12-30 Atrix Laboratories, Inc. Polymeric compositions useful as controlled release implants
US4938763B1 (en) 1988-10-03 1995-07-04 Atrix Lab Inc Biodegradable in-situ forming implants and method of producing the same
US5324519A (en) 1989-07-24 1994-06-28 Atrix Laboratories, Inc. Biodegradable polymer composition
US5558880A (en) 1989-12-22 1996-09-24 Janssen Pharmaceutica Inc. Pharmaceutical and other dosage forms
NL9000634A (nl) 1990-03-20 1991-10-16 Catharina Ziekenhuis Stichting Suspensie-injectiepreparaat op waterbasis, werkwijze voor de bereiding daarvan en toepassing van dit preparaat voor pijnbestrijding.
US5069909A (en) 1990-06-20 1991-12-03 Cygnus Therapeutic Systems Transdermal administration of buprenorphine
US5486362A (en) 1991-05-07 1996-01-23 Dynagen, Inc. Controlled, sustained release delivery system for treating drug dependency
HU219487B (hu) 1993-11-19 2001-04-28 Janssen Pharmaceutica Nv. Riszperidont tartalmazó mikrorészecskék, eljárás előállításukra, alkalmazásuk és ezeket tartalmazó gyógyászati készítmények és előállításuk
BR9507313A (pt) 1994-04-08 1997-10-07 Atrix Lab Inc Composição liquida de liberação adequada para a formação de um implante de liberação controlada sistema polimérico curativo filmico microporoso biodegradável precursor de implante de liberação controlada para a implantação em um indivíduo polímero termoplástico solvente orgánico composicão de pré-polimero liquido componente de liberação controlada agente ativo uso da composição liquida de liberação e processos para forma um implante microporoso de liberação prolongada e para liberar um agente ativo em um individuo
US5453425A (en) 1994-07-11 1995-09-26 Janssen Pharmaceutica N.V. Risperidone oral formulation
US7833543B2 (en) 1995-06-07 2010-11-16 Durect Corporation High viscosity liquid controlled delivery system and medical or surgical device
US20030211157A1 (en) 1996-05-06 2003-11-13 Simon David Lew Semi-sol delivery blend for water soluble molecules
US5792477A (en) 1996-05-07 1998-08-11 Alkermes Controlled Therapeutics, Inc. Ii Preparation of extended shelf-life biodegradable, biocompatible microparticles containing a biologically active agent
CA2257303C (en) 1996-06-17 2006-04-04 Janssen Pharmaceutica N.V. Biconvex rapidly disintegrating dosage forms
US6261583B1 (en) 1998-07-28 2001-07-17 Atrix Laboratories, Inc. Moldable solid delivery system
US6143314A (en) 1998-10-28 2000-11-07 Atrix Laboratories, Inc. Controlled release liquid delivery compositions with low initial drug burst
US6565874B1 (en) 1998-10-28 2003-05-20 Atrix Laboratories Polymeric delivery formulations of leuprolide with improved efficacy
US6194006B1 (en) 1998-12-30 2001-02-27 Alkermes Controlled Therapeutics Inc. Ii Preparation of microparticles having a selected release profile
JP4913298B2 (ja) 1999-08-27 2012-04-11 ブルックウッド ファーマシューティカルズ，インコーポレイティド 注射可能なブプレノルフィン微粒子組成物及びその使用
US6461631B1 (en) 1999-11-16 2002-10-08 Atrix Laboratories, Inc. Biodegradable polymer composition
US6264987B1 (en) 2000-05-19 2001-07-24 Alkermes Controlled Therapeutics Inc. Ii Method for preparing microparticles having a selected polymer molecular weight
WO2002067991A1 (en) 2001-02-23 2002-09-06 Genentech, Inc. Erodible polymers for injection
US20040018238A1 (en) 2001-02-26 2004-01-29 Shukla Atul J Biodegradable vehicles and delivery systems of biolgically active substances
US6558702B2 (en) 2001-04-13 2003-05-06 Alkermes Controlled Therapeutics, Inc. Method of modifying the release profile of sustained release compositions
US20140271788A1 (en) 2013-03-15 2014-09-18 Monosol Rx, Llc Sublingual and buccal film compositions
JP5078217B2 (ja) 2001-11-14 2012-11-21 デュレクト コーポレーション 注入可能なデポー組成物およびそれらの使用
US7041320B1 (en) 2002-05-31 2006-05-09 Biotek, Inc. High drug loaded injectable microparticle compositions and methods of treating opioid drug dependence
AU2003240493B2 (en) 2002-05-31 2008-06-12 L. Molteni & C. Dei Fratelli Alitti Societa' Di Esercizio S.P.A. Implantable polymeric device for sustained release of buprenorphine
EP1581181B1 (en) 2002-11-06 2008-12-24 ALZA Corporation Controlled release depot formulations
JP2006516963A (ja) 2003-02-04 2006-07-13 クリサリス テクノロジーズ インコーポレイテッド エアロゾル製剤及びブスピロン、ブプレノルフィン、トリアゾラム、シクロベンザプリン及びゾルピデムのエアロゾル送出
EP1622540A4 (en) 2003-03-11 2009-12-30 Qlt Usa Inc PREPARATIONS OF ANTI-CANCER AGENTS DEPENDENT ON THE CELLULAR PROGRAM
AU2004245022A1 (en) 2003-05-30 2004-12-16 Alza Corporation Implantable elastomeric depot compositions, uses thereof and method of manufacturing
CN101862455A (zh) 2003-06-26 2010-10-20 普西维达公司 原位胶凝的药物递送系统
FI20045223L (fi) 2004-06-15 2005-12-16 Bioretec Oy Monitoiminen biohajoava komposiitti ja kirurginen implantti, joka käsittää mainitun komposiitin
US20050032781A1 (en) 2003-08-06 2005-02-10 Elliot Ehrich Methods for administering active agents to CYP 2D6 sensitive patients
US20050048115A1 (en) 2003-08-27 2005-03-03 Murty Mangena Buprenorphine microspheres
US20050281879A1 (en) 2003-11-14 2005-12-22 Guohua Chen Excipients in drug delivery vehicles
US20050106214A1 (en) 2003-11-14 2005-05-19 Guohua Chen Excipients in drug delivery vehicles
US8329203B2 (en) 2004-01-12 2012-12-11 The Trustees Of The University Of Pennsylvania Drug-containing implants and methods of use thereof
US8221778B2 (en) 2005-01-12 2012-07-17 The Trustees Of The University Of Pennsylvania Drug-containing implants and methods of use thereof
BRPI0511807C8 (pt) 2004-06-04 2021-05-25 Camurus Ab pré-formulação, processo de formação de uma pré-formulação e uso da mesma
US8313763B2 (en) 2004-10-04 2012-11-20 Tolmar Therapeutics, Inc. Sustained delivery formulations of rapamycin compounds
BRPI0516308A2 (pt) 2004-10-04 2010-06-15 Qlt Usa Inc composição fluida, métodos de tratamento de uma doença ou disfunção, métodos de liberação local ou sistêmica de um agente biológico, implantes, método de formação de um implante, kit de agente biológico e usos de uma composição fluida
AU2005304435B8 (en) 2004-11-10 2011-06-23 Tolmar Therapeutics, Inc. A stabilized polymeric delivery system
WO2006065951A2 (en) 2004-12-15 2006-06-22 Qlt Usa, Inc. Sustained delivery formulations of octreotide compounds
US8852638B2 (en) 2005-09-30 2014-10-07 Durect Corporation Sustained release small molecule drug formulation
AU2006316607A1 (en) 2005-11-21 2007-05-31 Schering-Plough Pty. Limited Pharmaceutical compositions comprising buprenorphine
US20090239891A1 (en) 2006-03-01 2009-09-24 Shukla Atul J Sustained Release Dosage Forms of Analgesic Medications
US8076448B2 (en) 2006-10-11 2011-12-13 Tolmar Therapeutics, Inc. Preparation of biodegradable polyesters with low-burst properties by supercritical fluid extraction
DK2079767T3 (da) 2006-10-11 2014-10-27 Tolmar Therapeutics Inc Fremstilling af bionedbrydelige polyestere med lave burst-egenskaber ved ekstraktion med et superkritisk fluid
HRP20231117T3 (hr) 2007-02-15 2023-12-22 Tolmar International Limited Poli-(laktid-ko-glikolid) sa smanjenim efektom naglog oslobađanja
MX337286B (es) 2007-05-25 2016-02-22 Indivior Uk Ltd Formulaciones de transferencia sostenida de compuestos de risperidona.
MX2010002409A (es) 2007-09-03 2010-05-19 Nanotherapeutics Inc Composiciones y metodos para la distribucion de farmacos escasamente solubles.
US20090181068A1 (en) 2008-01-14 2009-07-16 Dunn Richard L Low Viscosity Liquid Polymeric Delivery System
KR101079513B1 (ko) * 2009-05-13 2011-11-03 삼성전기주식회사 범프 인쇄장치 및 그 제어방법
US8475832B2 (en) 2009-08-07 2013-07-02 Rb Pharmaceuticals Limited Sublingual and buccal film compositions
US9272044B2 (en) 2010-06-08 2016-03-01 Indivior Uk Limited Injectable flowable composition buprenorphine
GB2481018B (en) 2010-06-08 2015-03-18 Rb Pharmaceuticals Ltd Injectable flowable composition comprising buprenorphine
US8975270B2 (en) * 2010-06-08 2015-03-10 Rb Pharmaceuticals Limited Injectable flowable composition comprising buprenorphine
GB2481017B (en) 2010-06-08 2015-01-07 Rb Pharmaceuticals Ltd Microparticle buprenorphine suspension
DK2706986T3 (en) * 2011-09-19 2015-06-01 Orexo Ab NEW ADDICTION PREVENTING PHARMACEUTICAL COMPOSITION FOR TREATMENT OF OPIOID ADDICTION
SI2877155T1 (sl) 2012-07-26 2021-04-30 Camurus Ab Opioidne formulacije
TWI473863B (zh) 2012-12-19 2015-02-21 Nanya Plastics Corp 一種可剝離保護膜及其組成物配方
GB201404139D0 (en) * 2014-03-10 2014-04-23 Rb Pharmaceuticals Ltd Sustained release buprenorphine solution formulations
GB201419091D0 (en) 2014-10-27 2014-12-10 Camurus Ab Formulations
EP3215223B1 (en) 2014-11-07 2020-07-01 Indivior UK Limited Buprenorphine dosing regimens
CN107257681A (zh) 2014-12-23 2017-10-17 卡姆拉斯公司 控释配制品
GB201516554D0 (en) 2015-09-18 2015-11-04 Camurus Ab Controlled-release formulations
US10646484B2 (en) 2017-06-16 2020-05-12 Indivior Uk Limited Methods to treat opioid use disorder
AU2018283724B2 (en) 2017-06-16 2021-08-19 Indivior Uk Limited Methods to treat opioid use disorder

Also Published As

Publication number Publication date
AU2015341490B2 (en) 2020-08-13
NZ731309A (en) 2022-02-25
IL251870A0 (en) 2017-06-29
CA2965895A1 (en) 2016-05-12
US11839611B2 (en) 2023-12-12
AU2015341490C1 (en) 2021-03-11
CA3015557A1 (en) 2016-05-12
US20170354653A1 (en) 2017-12-14
US11000520B2 (en) 2021-05-11
US20220031692A1 (en) 2022-02-03
WO2016071767A1 (en) 2016-05-12
US20180243292A1 (en) 2018-08-30
ES2808150T3 (es) 2021-02-25
CA3015557C (en) 2019-07-16
AU2015341490A1 (en) 2017-05-18
EP3215223B1 (en) 2020-07-01
EP3215223A1 (en) 2017-09-13
US20160128997A1 (en) 2016-05-12
DK3215223T3 (da) 2020-08-03
SG11201703632WA (en) 2017-06-29
CA2965895C (en) 2019-08-06
US20230077787A1 (en) 2023-03-16

Similar Documents

Publication Publication Date Title
IL250672B (en) Treatment regimens using anti-nkg2a antibodies
IL249661A0 (en) Foam containing a heterogeneous mass
IL248706A0 (en) Heterogeneous mass containing foam
IL249081A0 (en) Heterogeneous mass containing foam
AU359340S (en) Mixer
PL3347054T3 (pl) Schematy dawkowania koniugatów przeciwciało anty-TF-lek
PL3237853T3 (pl) Zakrętka dozująca
HK1243368A1 (zh) 丁丙諾啡給藥方案
HK1259491A1 (zh) 給藥方案
AU357894S (en) Mixer
IL251413A0 (en) Composition of injectable buprenorphine
GB201521217D0 (en) Dosage regimens
RS60466B1 (sr) Dozirni uređaj
IL247083B (en) dose fgh–18
HUE055459T2 (hu) Cirkulációs szállítószalag
GB201418710D0 (en) Dosage regimen
GB201419494D0 (en) Variations
ZA201701203B (en) Conveyors
HK1219454A1 (zh) 用於賽艇比賽的便携物體
GB201402910D0 (en) Hopper
GB201408735D0 (en) Application coordination
GB201418708D0 (en) Dosage regimen
GB201415975D0 (en) One-call
GB201409826D0 (en) Project X
GB201400171D0 (en) Dosage regimen